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Background and Aim of the Project 
 
Primary immunodeficiency diseases are heritable disorders of immune 
system function [1].  Disruption of any part of the orchestrated immune 
response can result in an inability to control infections and subsequent illness.  
Apart from physical barriers, the immune response is composed from a 
diverse network of defenses, including cellular components and soluble 
mediators.  A proper normal immune response relies on the innate immune 
response that mounts rapid and nonspecific responses to initial infections and 
later on the adaptive response characterized by specific responses to a 
particular pathogen.  The innate immune response involves three major cell 
types: phagocytic cells, such as neutrophils and macrophages, natural killer 
(NK) cells and antigen-presenting cells, which are also involved in the 
induction of an adaptive immune response.  The adaptive immune system 
includes T and B lymphocytes and thus it can be divided into cellular and 
humoral responses.  However, these components of immune system work to 
maintain normal host function and resistance to infection in a well 
orchestrated and integrated unique system. 
In the last 5 decades since the first human host defect was identified, 
more than 200 primary immunodeficiency (PID) syndromes have been 
described.  PIDs can be divided into subgroups based on the component of 
the immune system that is predominantly affected, including T, B, NK 
lymphocytes, phagocytic cells and complement proteins [2].  Diseases in 
which lymphocyte functions are predominantly affected are commonly 
divided into three main groups.  The antibody deficiencies (B-cell or humoral 
immunodeficiencies), characterized by a genetic lesion that selectively affects 
antibody production, but a normal cell-mediated immunity; the cellular 
deficiencies, in which antibody production is largely normal, whereas cellular 
effector mechanisms are compromised; and the combined 
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immunodeficiencies, characterized by impairment of both effector arms of 
specific immunity. 
T-lymphocyte and B-lymphocyte responses are not independent of one 
another; for example, B cells can activate antigen-specific T cells for a 
cellular immune response, while an efficient B-cell antibody response 
depends in part on T-cell activation of B lymphocytes.  Thus, defects in 
either cell type have the potential to affect both cellular and humoral 
immunity to varying degrees. 
The last category contains the subgroup of severe combined 
immunodeficiency (SCID) disorders consisting of genetically determined 
blocks in the T-lymphocyte differentiation program.  The intrinsic 
impairment of T-cell development is variably associated with defective 
differentiation of other hematopoietic cell lineages.  In the absence of mature 
T cells, adaptive immunity is abrogated, resulting in a broad-spectrum 
susceptibility to multiple pathogens, among which a number of opportunistic 
microorganisms predominate.  In these cases, the diagnosis will most often 
be considered when infections are considered to be more frequent or severe, 
unusually resistant to standard therapies, or caused by unusual (opportunistic) 
organisms [1].  In fact, affected patients often present early in life with failure 
to thrive and disseminated infections.  Thus, SCIDs represent a group of 
diverse genetic disease affecting the immune system that share common 
clinical features including overwhelming viral and fungal infections.  
As a matter of fact, the discovery of more than 200 distinct clinical 
entities which differ in either the genetic cause or the altered immunological 
function led to an uncomparable increase in the knowledge of the intimate 
mechanism by which a proper immune response is generated.  Intriguingly, 
most of the genes whose alterations underlie PID are selectively expressed in 
hematopoietic cells with a few exception as, for example, Ataxia 
Telangiectasia Mutated (ATM) gene, also expressed in Purkinje cells, and 
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Adenosine Deaminase (ADA) which is ubiquitous.  This peculiarity leads to 
the increased susceptibility to infections, which represents the most 
remarkable presenting sign of immunodeficiencies.  This dogma, however, 
led to underestimate those novel immunodeficiencies, which have different 
features involving other non-hematopoietic tissues. 
In the 1996, for the first time, a novel form of SCID (MIM 601705; 
Pignata guarino syndrome) was described.  It represents the human 
equivalent of the well known murine phenotype defined as Nude/SCID [3] 
and it is the first example of SCID not primarily related to an hematopoietic 
cell abnormality, but rather to thymic aplasia [4].  Moreover, the hallmark of 
the Nude/SCID phenotype is congenital alopecia, from which the “Nude” 
term for the murine equivalent derived [5], always associated with a 
profound T-cell defect.  Thus, because of these atypical presenting signs, 
different from the clinical signs of the “classical” forms of SCID, the human 
Nude/SCID was identified only 30 years after the first description of the 
Nude phenotype in mice by Flanagan. 
In keeping with these observations, the aim of this thesis was to 
characterize some immunodeficiencies associated to different functional 
alterations in order to better understand the mechanisms involved in the 
pathogenesis of such immune diseases.  The results of this thesis by adding 
novel information in this field could be useful both in the clinical practice 
and in the basic research of immune disorders. 
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CHAPTER I 
 
Immunodeficiencies due to alteration of the 
thymic function 
 
In humans, lymphopoiesis occurs in bone marrow and thymus.  In 
particular, B lymphocytes mature within the bone marrow while T precursor 
cells leave the bone marrow and enter the thymus which is the only organ 
capable to support the differentiation and selection of mature T lymphocytes 
[6].  The thymus-dependent development of T cells requires that the 
developing thymocytes and thymic stromal cells have to communicate with 
each other in close proximity and remotely.  In fact, thymocyte development 
is based on a stringent repertoire selection after which only 1-3% of 
thymocytes can be exported from the thymus [7, 8].   
 
 7 
 
Moreover, developing thymocytes by coaching thymic stromal cells, 
provide the appropriate microenvironment necessary to promote and regulate 
further thymocytes development [9].  Therefore, the lympho-stromal 
communication is a bilateral coordination, or crosstalk, between architectural 
stromal cells and travelling thymocytes [10].  The thymic stromal 
compartment consists of several cell types that collectively enable the 
attraction, survival, expansion, migration, and differentiation of T-cell 
precursors.  The thymic epithelial cells (TECs) constitute the most abundant 
cell type of the thymic microenvironment and can be differentiated into 
morphologically, phenotypically, and functionally separate subpopulations of 
the postnatal thymus [11].  The epithelial compartment of the thymus 
originates from the endodermal layer of the anterior foregut [12].  During 
pharyngeal pouch development, these cells delaminate from the inner layer of 
the foregut and grow into the underlying mesenchymal tissue compartment 
that is of neural crest origin.  Expression analyses of the transcription factor 
Foxn1 have identified the ventral aspect of the third pharyngeal pouch 
endoderm as the only site from where the thymus primordium emerges [13].  
The early organogenesis of the thymus is closely coupled to that of the 
parathyroid gland, which has its origin in the dorsal part of the third 
pharyngeal pouch [11].  It begins to express Foxn1 at about E11.5, in mice.  
The Foxn1 gene is expressed in skin epithelial cells, hair follicles, and all 
subpopulations of thymic epithelial cells [14, 15].  In its function as a 
transcriptional activator, Foxn1 is absolutely required for the normal 
differentiation of hair follicles and thymus epithelial cells [5, 11, 16].  Foxn1 
encodes a transcription factor whose function is essential for subsequent 
epithelial differentiation; without it, colonization of the anlage by thymocyte 
progenitors fails [17] and thymopoiesis is aborted, resulting in severe 
immunodeficiency [18].  In fact, both mice with a recessive mutation of 
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Foxn1 lacking the DNA-binding domain and humans with a nonsense 
mutation resulting in a complete absence of a Foxn1 protein display the 
„nude‟ phenotype, which is characterized by hairlessness and congenital 
athymia.  Specifically, these Foxn1 mutations result in defective hair 
differentiation, although the hair follicles are normally specified and hair 
development is correctly initiated.  The formation of a thymus primordium in 
nude mice is normal up to the point when hematopoietic progenitors enter the 
wild-type thymus.  Importantly, neither the formation of the third pharyngeal 
pouch nor the patterning of the thymus primordium is affected by the lack of 
Foxn1 [18].  However, the epithelial cells of the nude anlage lack the ability 
to induce the entrance of hematopoietic progenitor cells into the epithelial 
cluster and thus preclude the generation of thymocytes [19].  It is still 
unknown which signal(s) determine(s) the site and also the size of the normal 
thymic anlage and whether these or other signals initiate Foxn1 expression.  
Clearly, genetic abnormalities involving the formation of pharyngeal pouches 
(such as deficiencies in Tbx1, Pbx1, Eya1, Six1) also have an impact on the 
thymus formation [20-22].  The most studied one is the gene encoding for the 
transcription factor Tbx1 involved in the development of the pharyngeal 
apparatus and its derivates [23-26].  Tbx1 belongs to the family of T-box 
transcription factors that are characterized by a common DNA-binding 
sequence, designated T-box, and the capacity to form combinatorial 
interactions with other transcriptional regulators [27].  A specific role for 
Tbx1 in thymus development has initially been inferred from a characteristic 
expression pattern in both the third pharyngeal pouch endoderm and the 
adjacent mesenchyme. By contrast, Tbx1 expression is excluded from neural 
crest cells and ectomesenchyme [11].  The homozygous loss of Tbx1 causes 
thymic hypoplasia and other severe pathologies affecting the derivates of the 
third and fourth pharyngeal arches, and these developmental anomalies are 
indistinguishable from changes observed after the deletion of premigratory 
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neural crest cells [23-26].  Interestingly, mice heterozygous for a null allele 
of Tbx1 demonstrate only a mild phenotype without thymus anomalies, while 
Tbx1-deficient mice transgenic for a bacterial artificial chromosome 
containing the human TBX1 display (among other anomalies) thymic 
hypoplasia or aplasia [28].  This result argues for a gene dosage effect of 
Tbx1 in the pathogenesis of DiGeorge syndrome. 
Briefly, the journey through the thymus began when committed 
lymphoid progenitor cell (CD34+) arise in the bone marrow and, via the 
blood, enters the thymus at the cortico-medullary junction [6].  In this phase, 
the progenitor cell not expresses the glycoprotein CD1a, which, instead, will 
be express by intrathymic lymphocytes [29].  In humans, this event occurs at 
the eighth week of gestation [30].  In the thymus, this cell lose the potential 
for B-cell and Natural-Killer (NK) cell development [31] resulting in a 
double negative (DN; no CD4 or CD8), committed T-cell precursor.  On the 
basis of the expression profiles of CD25 and CD44 showed by DN 
thymocytes during their maturation process it‟s possible discriminate four 
sequential stages of differentiation, such as: DN1, CD44+CD25-; DN2, 
CD44+CD25+; DN3, CD44-CD25+; DN4, CD44-CD25- [31].  Along this 
developmental pathway, immature DN thymocytes promote the 
differentiation of thymic stromal cells and trigger the formation of the 
cortical-epithelial environment in the thymus [32-35].  Therefore, the 
differentiation of thymocytes from the DN1 stage to the DN3 stage (CD4-
CD8-CD25+CD44-) regulate the differentiation of thymic epithelial cells 
(TECs) into cortical TECs (cTECs) that form the cortical environment in the 
thymus.  Concomitantly, DN thymocytes from the cortico-medullary junction 
migrate to the cortex where the maturation process began [6].  DN1 and DN2 
lymphocytes can potentially give rise to either  or .  The first TCR 
chains that are expressed early on thymocytes surface are the  and  chain; 
later,  chain is rearranged and the last one is the  chain.  The cells that 
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proceed along the  TCR pathway are the DN3 cells that first express pre-
TCR-  (pT ) that pairs with the TCR chain which is the product of a set 
of somatic DNA rearrangements that require expression of Recombination-
Activating gene (RAG1) and RAG2 proteins.  This is the first checkpoint ( -
selection) of T-cell development to the DN3 and DN4 stages.  In association 
with the pre-TCR  the CD3  complex is expressed at the cell surface to 
mediate signal transduction within the cell.  T cells that emerge from -
selection (late DN3 and DN4) undergo to recombination at the TCR a locus 
producing the second component chain of of the mature ab antigen receptor.  
During this stage the thymocytes begin to express co-receptor proteins, most 
often CD8 first, followed by CD4.  Eventually, a large population of double-
positive (DP; CD4+CD8+) -TCR-expressing immature cells is formed.  
Later, only a small aliquot of these DP cells with a functional rearranged 
TCR shall migrate into periphery [31].  Within the thymus, DP thymocytes 
undergo to positive and negative selection leading to single positive (SP) 
cells, CD4+CD8- or CD4-CD8+, that migrate to medulla.  In this thymic 
compartment the thymocytes began to express the homing receptor CD62L, a 
characteristic molecule of naïve cells.  Finally, they leave the thymus as 
mature naïve lymphocytes.  This population is chacarcterized by the 
expression of the RA isoform of the CD45 molecule, derived from the 
alternative splicing.  The isoform CD45RO is specifically of memory cells 
[36].  Later, it was proposed the combination use of different markers for 
naïve cells, such as CD62L and CCR7 [37].  In the newborn, the most of 
peripheral T cells (90%) shows a naïve phenotype, progressively decreasing 
during infancy (60%) and adulthood, with a paralleling increase of memory 
lymphocytes [38].  Thus the thymus is considered needful for the maturation 
of naïve cell, expecially for the CD4+ naïve cells.  Thus, the analysis of this 
cell subset could be useful to evaluate thymic output and subsequently to 
identify diseases due to abnormality of thymic function.  
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§ 1.1 The Nude/SCID phenotype as real human model of athymia 
More than 30 years from the original description of spontaneous murine 
disease, the first human equivalent of the Nude/SCID phenotype was 
described in 1996.  The identification of the human counterpart of nude 
mouse phenotype began with identification of two sisters, whose clinical 
phenotype was characterized by congenital alopecia, eyebrows, eyelashes, 
nail dystrophy and a severe T-cell immunodeficiency, inherited as an 
autosomal-recessive disorder [3].  The T-cell defect was characterized by 
severe functional impairment, as shown by the lack of proliferative response.  
The functional abnormality occurred in spite of the presence of a few 
phenotypically mature T cells, thus suggesting the qualitative nature of the 
defect [3].  Since alopecia and nail dystrophy are also found in other 
syndromes, such as dyskeratosis congenita (DC) [39, 40], other signs of this 
disease were investigated.  Differently from DC, major signs, such as 
abnormal pigmentation of the skin and mucosal leucoplakia, were lacking in 
Nude/SCID and the immunological abnormalities were different from those 
reported in patients with DC in both severity of clinical course and type of 
alterations [41, 42].  Moreover, both patients showed alopecia at birth and in 
one sib it still persisted after bone marrow transplantation, thus ruling out that 
it was secondary to an acquired skin damage.  This finding suggested that the 
alopecia in this patient was primitive in nature [3].  Furthermore, these 
features were similar to those reported in athymic mice, that completely lack 
body hair and in which restoration of a thymus did not lead to hair growth 
[43].  Taken together, these observations suggested an association between 
alopecia and the immunodeficiency reported in the 2 sisters, linked to a 
single gene defect [3].   
In humans, “FOXN1” is located on chromosome 17 [44] and it encodes 
a transcription factor mainly expressed in the epithelial cells of the skin and 
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thymus, maintaining the balance between growth and differentiation.  Later, a 
molecular analysis in these patients was performed and revealed the presence 
of a C-to-T shift at 792 nucleotide position in the sequence of the FOXN1 
cDNA, that leads to a nonsense mutation R255X in exon 4 (formerly exon 5), 
with a complete absence of a functional protein similar to the previously 
described rat and mouse Foxn1 mutations [45-47].   
Since the first description of these Nude/SCID patients other patients 
with a similar phenotype were identified.  In particular, a Nude/SCID patient 
was diagnosed in Portugal.  The newborn presented with alopecia and nail 
dystrophy associated with severe infections.  The screening for R255X 
mutation of FOXN1 gene revealed that the patient was homozygous for the 
mutation.  It should be noted that the patient was born to consanguineous 
parents, both from Lisbon. (communicated to European Society for 
Immunodeficiencies, 2006)  
Moreover, the 2 sisters in whom this mutation was found at the 
homozygous status, were born to consanguineous parents originating from a 
small community in southern Italy.  In this village additional patients of 
previous generations were affected with congenital alopecia and died early in 
childhood because of severe infections [48].  In order to identify an ancestral 
founder effect for this phenotype, in this population, that can be considered 
isolated for the geographical location of the village, a genetic screening for 
the presence of the FOXN1 R255X mutation was performed.  The study led 
to identify 55 subjects, corresponding to 6.52% of the studied population, 
who carried the mutation in heterozygousity [48].  All the affected cases 
belonged to an extended 7-generational-pedigree, founded by a single 
ancestral couple born at the beginning of the 19
th
 century from which four 
family groups originated.  The pedigree analysis revealed that 33.3% of 
heterozygotes inherited the mutant allele from their mother, whereas 66.7% 
from their father.  Moreover, this pedigree was also characterized by a high 
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rate of consanguineous matings, typical of small community; in fact, 14 out 
of 151 marriages were between consanguineous [48].   
The identified heterozygous subjects were examinated with particular 
regard to ectodermal alterations of hair and nails, in order to define whether 
the heterozygosity was associated with mild clinical signs.  The examination 
revealed no association between gross alteration of the hair and 
heterozygousity, while 39 of the 55 heterozygous subjects showed a nail 
dystrophy.  Of note, this alteration was not found in other control subjects 
and was not related to an acquired form of nail dystrophy.  The most frequent 
phenotypic alteration affecting the nails was koilonychia (“spoon nail”), 
characterized by a concave surface and raised edges of the nail plate, 
associated with significant thinning of the plate itself; the less frequent, 
canaliform dystrophy and a transverse groove of the nail plate (Beau line) 
[49].  However, the most specific phenotypic alteration was leukonychia, 
characterized by a typical arcifom pattern resembled to a half-moon and 
involving the proximal part of the nail plate.  These alterations of digits and 
nails were also reported in a few strains of nude mice.  FOXN1 is known to 
be selectively expressed in the nail matrix where the nail plate originates, 
thus confirming that this transcription factor is involved in the maturation 
process of nails and suggesting nail dystrophy as an indicative sign of 
heterozygousity for this molecular alteration [49]. 
Later, the identification of the haplotype for the FOXN1 locus, by 
analysing 47 chromosomes carrying the mutation R255X, led to identify the 
single ancestral event that underlies the human Nude/SCID phenotype.  As 
this form of SCID is more severe due to the absence of the thymus, a 
screening program for prenatal diagnosis in this population was considered 
most important for the identification of fetuses carrying the mutation.  During 
the screening program in this population a high rate of mortality in the first 
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trimester was also found.  This event was not justified by SCID per se thus 
suggesting the involvement of an unknown mechanism that caused mortality. 
The genetic counselling offered to couples at risk through the prenatal 
diagnosis by direct genetic analysis of FOXN1 led to identify an affected 
female fetus during the first trimester of pregnancy, thus indicating the 
importance of this effort.  The fetus was homozygous for R255X mutation 
and the autoptical examination revealed the absence of the thymus and a 
grossly abnormal skin which was tighter than usual and which showed basal 
hyperplasia and dysmaturity, suggestive of an impaired differentiation 
program.  These signs confirmed that FOXN1 is involved in thymic 
development and skin differentiation in humans.  Of note, the fetus also 
showed multiple-site neural tube defects, including anencephaly and spina 
bifida that could explain the high rate of mortality in utero observed in the 
described population.  Another aspect that led to consider the Nude/SCID 
mutation and anencephaly causally related is the fact that the other forms of 
SCID become clinically evident in post-natal life, when the protection of the 
newborn by the mother immune system declines.  Moreover, there was an 
evidence that the mouse Foxn1 gene is also expressed in epithelial cells of 
the developing choroids plexus, a structure filling the lateral, third and fourth 
ventricles of the embryonic brain [50].  Further studies on these aspects are 
performed on a second female fetus affected with Nude/SCID phenotype and 
belonging to the same family of the previous fetus.  She was examined for 
the presence of CNS developmental anomalies.  In particular, the abdominal 
sonography, revealed a morphologically normal brain, apart from a probable 
absence of the septum pellucidum, as suggested by failure to visualize cavum 
septi pellucidi (CSP) by means of ultrasound, in that only the medial wall of 
the frontal horn could be detected.  At this gestational age, CSP is a fluid-
filled cavity located in between the two layers of the septum pellucidum.  In 
the Nude/SCID fetus, autopsy failed to reveal any macroscopic abnormality 
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of brain structures, including choroid plexus, except the abnormality in the 
development of corpus callosum.  
Thus, these findings suggest that FOXN1 may also be implicated as co-
factor in the development of vital systems required for a proper fetus 
development, thus explaining the mortality in the first trimester, not justified 
by the SCID per se.  
These data have been published in a chapter of the book entitled 
Forkhead Transcription Factors: Vital Elements in Biology and Medicine, in 
Rivista Italiana di Genetica e Immunologia Pediatrica and in Journal of the 
Neurological Sciences.  (See below for the manuscripts). 
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§ 1.2  T-cell ontogeny in the absence of the thymus: a comparative study 
between Nude/SCID and DiGeorge syndromes. 
In nude mice the thymic agenesis is congenital and it closely 
resembles thymic agenesis of newborns affected with DiGeorge syndrome 
(DGS).  DiGeorge syndrome represents the most-frequent microdeletion 
syndrome in humans, with an estimated incidence of 1 in 4000 live births 
[51-53].  It is classified as a 22q11 microdeletion, along with velo-cardio-
facial syndrome and conotruncal anomaly face syndrome.  DGS is clinically 
heterogeneous because of the loss of different genes in the region 22q11 [54, 
55]. In particular, approximately 90% of the patients share a common 3 Mb 
hemizygous deletion of 22q11.2, encompassing approximately 30 genes and 
8% of the patients have smaller deletions of 1.5 Mb encompassing 24 genes 
[54].  A few DGS cases have defects in other chromosome, notably 10p13 
[56, 57].  22q11.2 deletion syndrome is also associated with neonatal 
hypocalcaemia due to hypoplasia of the parathyroid glands and susceptibility 
to infection due to thymic hypoplasia occurs in up to 80% [58, 59].  A variety 
of cardiac malformations may be seen including tetralogy of fallot and 
interrupted aortic arch [60].  Patients may exhibit dysmorphic features with 
micrognathia and auricular abnormalities (including low set ears and 
abnormal pinna folding).  Dysmorphic facial appearance in an individual 
with cardiac abnormalities or history of recurrent infection should raise 
suspicion for the diagnosis of 22q11.2 deletion syndrome [61].  A lot of 
studies have also reported an increased incidence of learning difficulties, 
behavioural problems and psychiatric disorders, [62] but the molecular origin 
of these neurobehavioral defects remains to be elucidated.  
A variety of mouse models phenocopying DiGeorge syndrome have 
shed new light on crucial genes involved in the aetiology of the DiGeorge 
syndrome [54, 63].  They have also revealed the role of genes that are not 
present in the microdeletion, but which modulate the severity and penetrance 
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of the DiGeorge-like phenotype [55].  All gene mutations described so far 
have been shown to affect the development of the pharyngeal apparatus, a 
vertebrate-specific, transient embryonic structure [55].  DiGeorge syndrome 
is a congenital anomaly characterized by defects derived mainly from the 
third and fourth pharyngeal pouches, with additional abnormalities possibly 
extending from the first to sixth pharyngeal arch and first to fifth pharyngeal 
pouch [64].  Typically, the heart, the parathyroids, and the thymus are 
involved [65, 66].  Formation and patterning of the pharyngeal apparatus 
involves organization and interaction of different cell types derived from all 
embryonic tissue layers [55].  The pharyngeal system consists of five 
pharyngeal arches appearing in the lateral wall of the foregut between 8 and 
11 days of embryonic development in the mouse and between 2 and 7 weeks 
of gestation in humans.  The arches are separated from each other externally 
by ectoderm-lined pharyngeal clefts and internally by endoderm-lined 
pharyngeal pouches.  The five arches develop in anterior-to-posterior order, 
and are numbered from 1 to 6 (the fifth arch, which is buried, is termed the 
sixth arch by convention).  Morphogenesis of the pharyngeal apparatus 
involves the initial segmentation and expansion of pharyngeal arches and 
pouches, followed by development of pharyngeal derivatives from these 
structures.  Genetic pathways regulate these processes in a complex spatial 
and temporal manner, but the players and molecular interactions involved in 
these dynamic genetic networks are only partially understood [55].  In 
22q11.2 deletion syndrome the defects in the thymus, parathyroid and 
conotruncal regions of the heart are believed be caused by impaired 
migration of neural crest cells into pouch ectoderm.  Disruption in the 
pathways of neural crest cell development in mice results in malformations 
similar to the 22q11.2 deletion phenotype.   
A variety of candidate genes have been identified [61].  Engineered 
segmental deletions of the murine Df1 regions syntenic to the human 
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22q11.2, transgenic complementation studies of genes within this locus, and 
single-gene-targeting experiments have revealed the significance of the 
transcription factor Tbx1 for the development of the pharyngeal apparatus 
and its derivates {Lindsay, 1999 #1781;Lindsay, 2001 #1918;Merscher, 2001 
#1919; [26].  Mice with these genetic alterations display most of the cardiac 
and pharyngeal arch defects observed in the 22q11.2 deletion syndromes. 
[11]  TBX1 belongs to a family of transcription factors that contain a DNA 
binding domain called „T-box‟.  Homozygous deletion of the Tbx1 gene in 
mice results in death in-utero. However, phenotypic features of 22q11.2 
deletion were detectable in the embryos including abnormal facial features, 
thymic and parathyroid hypoplasia and cardiac abnormalities. Heterozygous 
mutants exhibited a less penetrant phenotype, with varying degrees of 
absence or reduction in fourth pharyngeal arches [61].  A lot of deletion 
experiments have been performed revealing that Tbx1 has a specific time-
dependent role in the formation of the pharyngeal pouches and their 
derivatives.  In addition, these experiments revealed that Tbx1 may very 
likely regulate the segmentation of the pharynx through the proliferative 
control of the endodermal epithelium thus influencing regular thymus 
organogenesis [11].  In fact individuals with chromosome 22q11.2 deletion 
syndrome frequently have a small hypoplastic thymus.  Generally, 
individuals with an absent thymus and a profound T-cell lymphopoenia have 
been described as having complete DiGeorge syndrome, whereas most 
patients have a milder form of immunodeficiency and are described as having 
partial DiGeorge syndrome [67].  
Infants with complete DiGeorge syndrome have absence of thymic 
function in addition to other defects of the third and fourth pharyngeal 
pouches [68, 69].  These profoundly immunodeficient infants represent less 
than 1% of patients with DiGeorge syndrome [53]. 
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  In the past, categorization of patients with DiGeorge syndrome as 
athymic required both profoundly low numbers of circulating T cells and 
very low T-cell proliferative responses to mitogens [64].  The size of the 
thymus correlates poorly with peripheral T-cell counts, suggesting that 
sources of extrathymic production of T cells might exist [70].  Evidence 
exists for the presence of microscopic remnants of thymic epithelial cells.  
One retrospective study showed the presence of retropharyngeal thymus 
tissue in children with features of DiGeorge syndrome [71].  Several centres 
have measured thymic function in patients diagnosed with DiGeorge 
syndrome on the basis of clinical features or of detection of the 22q11.2 
deletion.  Although a large proportion of patients has an absent or hypoplastic 
thymus at the time of cardiac surgery, most seem to have only a minor 
immune defect [53, 68, 72-74].  Most studies reported that patients show a 
reduction in the mean or median proportion and number of CD3+ T cells and 
CD4+ T helper cells compared with that of age-matched controls [72-77].  
The function of T cells, as measured by incorporation of H3-thymidine to 
quantify lymphocyte proliferation after stimulation with mitogens, is 
generally normal [68, 72, 74, 75].  One additional feature is the expanded 
proportion of B cells (CD19+), natural killer T cells (CD16+CD56+) in 
patients compared with controls [72, 73, 76].  Although the rate of decline of 
T-cell numbers in patients with chromosome 22q11.2 deletion syndrome is 
slower than is that of controls, the T-cell population is smaller than is that of 
healthy controls throughout childhood [73, 75].  Notably, it was described 
that athymia can be present in patients with DiGeorge Syndrome who have 
significant numbers of T cells that can respond to mitogens [64].  For long 
time DiGeorge syndrome (DGS) was erroneously considered the human 
counterpart of the murine Nude phenotype.  This association was based on 
the absence of the thymus leading to a similar immunological phenotype in 
both Nude mouse and DiGeorge patient.  However, in-depth analysing these 
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two phenotypes, they appear more different.  First of all, congenital alopecia 
and skin abnormalities, that represent the main features of the Nude/SCID 
phenotype, are absent in DGS.  Moreover, even though they share the 
absence of the thymus, some immunologic aspects argue in favour of the 
Nude/SCID phenotype as the real model of human athymia.  Thus, aim of 
this study was to identify differences in the T-cell ontogeny blockage in two 
different models of human athymic diseases.  A particular attention will be 
paid to the comparison of T-cell pool maturation and functionality in 
Nude/SCID and DGS to define possible sites of extrathymic T-cell 
maturation. 
Seven Nude/SCID patients and 14 DGS patients were included in this 
study as detailed in Table 1.  
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Results 
 
Peripheral lymphocytes characterization of Nude/SCID and DGS 
patients  
In order to analyze differences in peripheral cell pool between 
Nude/SCID and DGS patients, the presence of some cellular markers was 
evaluated through cytofluorimetry.  Since one of the sample was obtained 
from cord blood of Nude/SCID fetus, first of all maternal contamination was 
excluded through STRs analysis on maternal and fetal DNA thanks to the 
collaboration of the Department of Medical Biochemistry and Biotechnology 
(DBBM)-CEINGE of “Federico II” University of Naples.  As shown in 
Figure 1, the STR analysis of the cord blood revealed the presence of half of 
STR as maternal inherited thus excluding maternal contamination of the fetal 
sample. 
 
 
  
 An extensive analysis of immunophenotype in these two groups of 
patients was performed.  First of all the main lymphocytes subsets were 
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evaluated: stem cells (CD34+), T cells (CD3+), B cells (CD19+), NK cells 
(CD16+CD56+).  The results are indicated in Table 2.  
 
 
 
 
 
 
 
 
 
Moreover, to further characterize the T lymphocytes detected in 
periphery, specific markers of T cells subsets were analysed: T Helper 
lymphocytes (CD3+CD4+), citotoxic T lymphocytes (CD3+CD8+), TNK 
lymphocytes (CD3+CD16+CD56+) and CD3+CD7+ lymphocytes.  The 
values obtained are shown in Figure 2A.   
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Moreover, to evaluate, in the cord blood, the presence of naïve cells of 
both CD4+ and CD8+ cell compartment specific of thymic production, the 
following subsets were analyzed: CD4+CD45RA+, CD4+CD62L+, 
CD8+CD45RA+, CD8+CD62L+.  The data obtained for these cell 
populations are showed in the Figure 2B.  
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Evaluation of lymphocytes proliferation in Nude/SCID and DGS patients 
 In order to evaluate differences in the lymphocytes proliferation 
between Nude/SCID and DGS patients, the proliferation assay after 
mitogenic stimulation with PHA, PWM, CON-A and CD3 was performed.  
The results are indicated in the Figure 3. 
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§ 1.3 Conclusive remarks 
 Human Nude/SCID and DGS sindromes are characterized by severe 
anomalies of thymus development due to different genetic causes.  Even 
thought these two syndromes share the absence of the thymus they appear 
quite different for both immunological and clinical phenotypes (see Table 3).   
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 Athymia in Nude/SCID syndrome is associated with a high 
susceptibility to infections leading to death in the first months of life.  To 
date, the only therapeutical approach for these patients is represented by 
BMT, even though it is not able to recover the correct immune function.  
Contrary, in DGS patients the athymia is not associated to an increase 
susceptibility to infections and generally they died for the presence of 
cardiopathy.  By an immunological point of view, the severe infections in 
Nude/SCID patients are due to a severe reduction of T lymphocytes, while in 
DGS patients they are mild and generally associated to a slow reduction of T 
lymphocytes.  Most important, in Nude/SCID patients the lymphocytes are 
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not functional, while in DGS patients they normally respond to mitogenic 
stimulation in vitro thus justifying the lower infections in these patients than 
in Nude/SCID ones.  Aiming to better characterize the differentiative 
blockage in these two different athymic diseases, the data obtained from this 
work revealed that in both Nude/SCID and DGS patients the CD34+ stem 
cells were normal, while CD3+ T lymphocytes were reduced in both, but 
with a more small aliquot in Nude/SCID patients than in DGS patients.  The 
increase of B lymphocytes (CD19+) percentage in Nude/SCID patients was 
due to the reduction of T cells and it represented only a relative increase with 
no clinical implications.  Contrary, in DGS patients the B lymphocytes were 
normal.  The NK cells (CD16+CD56+) were normal in both syndromes.  
Thus, only T cell compartment was altered in both syndromes.  Further 
analysis of T cells revealed that the CD3+CD4+ cells were reduced in both 
syndromes, but more in Nude/SCID patients.  The number of CD3+CD8+ 
cells was normal in DGS patients, while it was reduced in Nude/SCID.  
However, in Nude/SCID syndrome, the reduction of CD3+CD8+ 
lymphocytes was lower than of CD3+CD4+ compartment thus implying that 
CD3+CD8+ cells can developed in a thymus independent manner.  The 
evaluation of NKT cells (CD3+CD16+CD56+) revealed a reduction in 
Nude/SCID patients, while they were close to normal in DGS patients.  Since 
CD7 molecule is expressed on early CD3+ cells and then it progressively 
disappeared on naïve and memory T cells [78], in both syndromes the 
CD3+CD7+ cells were analysed in order to evaluate the presence of 
immature cells developed in the absence of the thymus.  The cytoflurimetric 
analysis revealed a markedly reduction of CD3+CD7+ cells in Nude/SCID 
patients, while in DGS they were close to normal.  The presence of this cell 
population in DGS suggests the presence of an alternative pathway for the 
development of such cells.   
 46 
 By analysing the naïve compartment, no CD4+ naïve 
(CD4+CD45RA+, CD4+CD62L+) cells were detected in Nude/SCID 
patients, while they were present in DGS patients, even though in a small 
number.  Also the analysis of the CD8+ naïve (CD8+CD45RA+, 
CD8+CD62L+) cells revealed the absence of these cell populations in 
Nude/SCID patients but the presence, even though under the normal values, 
of these cells in DGS patients.   
 Moreover, the evaluation of the proliferative capacity of the 
lymphocytes from both syndromes revealed a normal functionality in DGS 
patients opposite to what documented in Nude/SCID patients who didn‟t 
respond to mitogenic stimulation.  This result is in keeping with the different 
clinical phenotype in the two syndromes, characterized by severe and 
untreatable infections in Nude/SCID patients.   
 Together these data indicate a severe reduction of both helper and 
citotoxic T cells in Nude/SCID patients, unlike DGS patients who only 
showed a slowly reduction of T cells which were also functional.  Thus, even 
though these two syndromes share the athymia, their immunological 
phenotypes are completely different.  Moreover, an in dept characterization 
of T cell compartment revealed, in DGS, the presence of different cell 
subsets which were poorly represented in Nude/SCID.  All together, these 
observations support the hypothesis that an alternative site could ensure T 
cell production in absence of the thymus.  As it is clear from our data, this 
site of extrathymic T cell development is probably altered in Nude/SCID 
syndrome since no mature T cells were found.  This hypothesis is strongly 
supported by other data on NKT (CD3+CD16+CD56+) cells and on 
CD3+CD7+ cells.  In particular, NKT cells are considered of thymic origin, 
but since they were also found in liver, spleen and bone marrow and in 
athymic mice, they are supposed to develop outside the thymus, probably in 
the liver [79].  Thus, the presence of these cells in the DGS patients is 
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probably due to an extrathymic site of lymphocytes development which was 
absent in the Nude/SCID syndrome.  Moreover, also the presence of the 
CD3+CD7+ cells, probably representing precursor cells, argues in favour of a 
population developing outside the thymus in that, in the mouse, a cell 
population CD2+CD3+CD7+ probably of intestinal origin, was documented 
[80].    
 The main difference between Nude/SCID and DGS is represented by 
the presence of alopecia and skin keratynocytes alterations in Nude/SCID, 
absent in DGS.  These abnormalities are due to the absence of the 
transcription factor FOXN1 responsible for Nude/SCID syndrome, which is 
expressed both in thymic and epithelial cells.  So, since the main difference 
between these two syndromes is represented by skin abnormalities, it was 
supposed that the skin, which is normal in DGS, can act as a surrogate organ 
capable to support T cell differentiation in the absence of the thymus.  This 
hypothesis is supported by the observation that cellular colture containing 
skin cells expressing FOXN1 and hematopoietic precursor cells are able to 
support lymphocyte differentiation in vitro [81].   
 In conclusion, the data emerging from this study lead to consider the 
Nude/SCID syndrome as real model of human athymia in that in DGS it was 
not documented a real differentiative blockage of T cell development.    
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   CHAPTER II 
 
Immunodeficiencies due to alteration of the 
cerebellar function: the Ataxia Telangiectasia 
 
Among those PIDs whose causing genes are not selectively expressed in 
the hematopoietic compartment there is Ataxia-telangiectasia (A-T), a rare 
autosomal recessive disorder, characterized by progressive neurological 
dysfunction, especially affecting the cerebellum, oculo cutaneous 
telangiectasia, high incidence of neoplasms and hypersensitivity to ionizing 
radiations [82, 83].  
Immunodeficiency is present in 60-80% of individuals with A-T, it is 
variable and do not correlate well with the frequency, severity or spectrum of 
infections  [84].  The immunodeficiency is progressive and the most 
consistent immunodeficiency reported is poor antibody response to 
pneumococcal polysaccharide vaccines [84].   Moreover, serum 
concentration of the immunoglobulins IgA, IgE and IgG2 may be reduced.  
Approximately 30% of individuals with A-T who have immunodeficiency 
have T-cell deficiencies.  At autopsy, virtually all individuals have a small 
embryonic-like thymus.  Unlike most immunodeficiency disorders, the 
spectrum of infection in individuals with A-T does not comprise 
opportunistic infections.  Some individuals develop chronic bronchiectasis 
and the frequency and severity of infections correlates more with general 
nutritional status than with the immune status.  Individuals with frequent and 
severe infections appear to benefit from intravenous immunoglobulin (IVIG) 
replacement therapy [84]; however, longevity has increased substantially 
even in individuals not receiving IVIG.  Immunological abnormalities mainly 
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include impaired antibody responses, T-cell lymphopenia, primarily affecting 
CD4+ lymphocytes, and impaired proliferative response to mitogens and 
antigens. However, severe infections are uncommon in A-T [85]. On the 
contrary, clinical signs related to the progressive neurodegeneration are 
overwhelming and dramatically affect the quality of life.  Purkinje cells are 
thought be selectively depleted, thus resulting in the progressive cerebellar 
atrophy of the cortex associated with significant thinning of the molecular 
layer, as revealed by autopsy and biopsy studies [86, 87].   
A-T is caused by mutation of A-T mutated gene product (ATM) [83].  
ATM is a protein kinase, that regulates those responses required for cell 
survival in response to DNA double-strand breaks (DSBs) caused by ionizing 
radiation, DNA damage agents and DNA recombination [88].  
Unfortunately, currently there is no effective treatment for A-T, but 
supportive care of neurological symptoms, as physical, occupational and 
speech/swallowing neurorehabilitation. Eventually, the progressive 
neurodegeneration and pneumonia are a frequent cause of death in patients 
with A-T. 
 
§ 2.1 In Ataxia Telangiectasia patients betamethasone response is 
inversely correlated to cerebellar atrophy and directly to antioxidative 
capacity 
The central nervous system is particularly vulnerable to oxidative stress 
due to its high rate of metabolism and to the disproportionately low levels of 
its oxidative defence mechanisms [86].  The increased and unopposed ROS 
production can lead to neurotoxicity those results in neural damage and 
eventually in cell death.   
Even though A-T is a non-curable disease, recently, Broccoletti et al. 
demonstrated a dramatic improvement of cerebellar functions in a few A-T 
patients after a short-term betamethasone therapy [87].  The highest clinical 
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improvement was on speech disturbance, stance, and finger chase items [87].  
As the effect of betamethasone was transient in nature, it should be argued 
that the intimate mechanism of this pharmacological action regards some still 
unidentified steroid-dependent biochemical event.  This is not surprising, 
because a permanent reversion of the molecular alteration is not expected, 
and the drug presumably acts on the damage derived from ATM dysfunction.  
Of note, ATM protein, after its autophosphorylation, activates multiple 
substrates involved in cell cycle regulation, such as p53 and, eventually, 
leads, cooperating with other DNA repairing factors, to cell cycle arrest.  
ATM is also involved in sensing and modulating intracellular redox status, 
even though it is not clear whether ATM itself is directly involved in ROS 
production [89, 90].  However, ATM deficiency causes oxidative damage to 
proteins and lipids in brain, testes and thymus.  Cells have developed a wide 
array of protective mechanisms against ROS, including small reducing 
molecules, antioxidative enzymes and damage/repair systems [85].  One of 
the small reducing molecules is glutathione (GS), which appears in the cells 
in both its oxidized and reduced (GSH) forms.  It works in detoxifying 
specific ROS by itself or in combination with other enzymes, such as SOD, 
which converts superoxide radicals into H2O2 and O2, catalase, glutathione 
peroxidase (PHGPx) and glutathione-S-transferases.  Oxidants 
overproduction and/or dysfunction of endogenous antioxidant defenses result 
in oxidative stress induced injury with damage to all the major classes of 
biological macromolecules, such as nucleic acids, proteins, lipids and 
carbohydrates.  The CNS is particularly vulnerable to oxidative stress due to 
its high rate of metabolism and to the disproportionately low levels of its 
oxidative defense mechanisms [86].  The increased and unopposed ROS 
production can lead to neurotoxicity that results in neural damage and 
eventually in cell death.  
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Due to the importance of the topic and since the intimate molecular 
mechanism by which betamethasone led to this effect remains unclear, aim of 
this study was to evaluate whether the beneficial effect of betamethasone 
therapy could be mediated by interference in ROS generation/neutralization 
process.  Thus, in this part of my study, we measured in a small cohort of A-
T patients direct markers of ROS production, during a short-term steroid 
treatment. 
This study has been published on The European Journal of Neurology, 
for the manuscript see below.  
 52 
Publications 
 
 53 
 
 54 
 
 55 
 
 56 
 
 57 
§ 2.2 Conclusive remarks 
 Even though A-T is non-curable Broccoletti et al. demonstrated an 
improvement of the cerebellar functions in 6 A-T patients after a short-term 
betamethasone therapy (0.1 mg/kg/day for 10 days) [87].  Although the 
clinical response to betamethasone was evident, there was no evidence 
indicating the intimate mechanism of action of this drug in A-T.   
 In this study, on the basis of our finding, we concluded that 
betamethasone response in A-T patients is inversely correlated to cerebellar 
atrophy and directly to antioxidative capacity.  The importance of this study 
relies principally on the severity of the neurological signs.  In fact, this 
childhood disease is characterized by progressive impairment of gait and 
speech, oculomotor apraxia (inability to move the eyes from one object to 
another), oculocutaneous telangiectasia (dilated blood vessels), cerebellar 
atrophy, sterility and radiosensitivity [91].  A-T is primarily a syndrome of 
progressive cerebellar ataxia but more diffuse changes to the CNS are also 
evident.  Cerebellar degeneration in A-T manifests as dystrophic changes 
involving the dendrites and axons of Purkinje cells and ectopic Purkinje cells 
are evident.  Of all the features of A-T the progressive cerebellar 
neurodegeneration is the most debilitating leading to peripheral neuropathy 
and eventually to spinal muscular atrophy.   
 Thus, any effective treatment for A-T would ideally involve 
prevention or at least slowing of the progressive neurodegeneration.  As 
mentioned above, at present there is no therapy available to cure or prevent 
the progress of A-T, but it is possible to alleviate some of the symptoms 
associated with immunodeficiency and deficient lung function but neither the 
cancer predisposition nor the progressive neurodegeneration can be 
prevented.   
 There is no cure for the progressive neurodegeneration with 
conventional therapies but some promise exists.  Most importantly, the 
 58 
rescue of the neurological function, at some extent, suggests that cell loss is 
an ultimate feature in A-T and those biochemical alterations, presumably 
reversible, precede for a long time cerebellar atrophy.   
 This study on the implicated mechanisms may open an important 
window on novel therapeutic agents capable of controlling neurological 
symptoms in A-T. 
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                              CHAPTER III 
 
Immunodeficiencies due to alteration of genes 
expressed in hematopoietic cells 
 
Several molecules, involved in the intracellular communication network, 
have been identified as the cause of many forms of SCID.  In most cases, 
unlikely from the above described SCIDs, these molecules are exclusively 
expressed in hematopoietic cells, being involved in cell development and/or 
functionality of terminal differentiated cells of immune system. 
Defects of cytokine-mediated signaling are responsible for the majority 
of SCID in humans affecting both cell development and functionality of 
differentiated cells.  SCIDX1 accounts for 40% of all cases of SCID and is 
caused by mutations of the IL-2 receptor g gene (IL2RG), which encodes for 
the common  chain ( c) shared by cytokine receptors for IL-2, IL-4, IL-7, 
IL-9, IL-15, and IL-21.  In particular, IL-7 mediates expansion of early 
thymocyte progenitors, whereas IL-15 plays a role in NK cell development 
[92].  Accordingly, patients with SCIDX1 lack both T and NK cells, whereas 
they have a normal number of circulating B lymphocytes [93].  The c is 
physically and functionally coupled to the intracellular tyrosine kinase Janus 
kinase (JAK) 3, which delivers c-mediated intracellular signaling.  Hence 
defects of JAK3 result in an autosomal recessive form of SCID with an 
immunologic phenotype undistinguishable from that of SCIDX1 [94].  
Mutations of the IL7R gene (encoding for the  chain of the IL-7 receptor) 
abrogate T-lymphocyte development but leave B-cell and NK-cell 
development intact [95]. 
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Among the immunodeficiencies due to alterations of functionality of 
lymphocytes, there is the Hyper IgE syndrome (HIES).  It is a rare primary 
immunodeficiency characterized by the triad of elevated IgE and 
eosinophilia, eczema, and recurrent skin and pulmonary infections [96].  
Dominant negative mutations in the signal transduction and activation of 
transcription (STAT) 3 gene account for the vast majority of autosomal 
dominant (AD) and sporadic cases, but the pathogenesis of some of the 
varied clinical features of HIES remains poorly understood [97, 98].  
Autosomal recessive diseases with elevated IgE that have been grouped with 
HIES are considerably more rare than the autosomal dominant STAT3-
deficient form of HIES.  They are clinically distinct, more severe, and may 
be associated with autoimmunity and vasculitis [99].  Specific mutations 
have not been identified in these patients.  However, a single case of 
homozygous mutation leading to a premature stop in Tyk2 was found [100].  
Tyk2 is a key signal transduction molecule upstream of STAT3 and therefore 
critical for the production of IL-6, IL-10, IL-12, IL-23, and IFN-α, many of 
the same cytokines involved with STAT3. 
 
§ 3.1 Alteration of IL-12R signalling in children with high serum level of 
IgE 
The immunophenotype of HIES has long implicated defects in both 
innate and adaptive immune responses, leading to the suspicion that 
cytokines and chemokines, which are involved in all aspects of the immune 
response, were likely to be involved in the pathogenesis of HIES [96].  
Cytokines are produced in response to diverse cellular stimuli and serve as 
growth factors and regulators of the immune response [96].  An appropriate 
immune response mostly relies on a well orchestrated Th1/Th2 dichotomy, 
whose hallmark is based on the capability of the individual subset to work in 
an autocrine fashion leading to amplify its own cell development and to 
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cross-regulate the other subset development and activity [101, 102].  It has 
been hypothesized that elevated serum levels of IgE are associated with a 
Th1/Th2 imbalance [103].  In particular, Th1 response is induced by IL-12 
produced by B cells and macrophages [104].  The receptor is up-regulated 
during T-cell activation and IL-12R 2 transcript is selectively expressed in 
Th1 cells following IL-12 stimulation, while IL-12R 1 is constitutively 
expressed in resting cells [105].  The transducing element of the receptor is 
the IL-12R 2 chain that functionally interacts with members of the family of 
Signal Transducers and Activators of Transcription (STAT), and in particular 
STAT4 [106].  This transcription factor is promptly phosphorylated on 
tyrosine residues upon receptor triggering [106].  Th1 cells develop in the 
presence of IL-12 and STAT4 signaling and secrete mainly IFN-  [107].  
Moreover, experimental evidence using the knock-out technology supports 
the concept that IL-12R/STAT signaling pathway plays a role for the 
induction of a Th1 response [108, 109].  Thus, by studying children with 
elevated serum IgE levels divided on the basis of the IgE values (> 2000 kU/l 
or < 2000 kU/l) the aims of this part of the study were to investigate at a 
functional level whether an impaired induction of Th1 response occurred in 
patients with elevated IgE serum levels, and whether such abnormalities were 
correlated with alterations of the IL-12 receptor signaling apparatus. 
The results of this study were published on Cellular Immunology.  See 
below for the paper. 
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§ 3.2 Conclusive remarks 
 In this study, we provided evidence of altered IL-12/IL-12R signaling 
in patients with very high IgE level, suggestive of an impaired Th1 induction.  
In particular, defective supershift of the STAT4 molecule following rIL-12 
stimulation of T-cell blasts was documented.  It is noteworthy that all the 
abnormalities herein described were observed only in patients with IgE levels 
higher than 2000 kU/l, which represent only a minority of patients, and not in 
atopic patients with an ordinary increase of IgE levels.  The cut-off of 2000 
kU/l is generally assumed as a presumptive sign to select patients at risk of 
being affected by Hyper-IgE Syndrome (HIES).  However, this syndrome 
was excluded in our patients by the absence of the typical clinical and 
immunological features [110, 111].  In particular, no recurrent skin 
infections, facial, skeletal and dentition anomalies were observed.  Thus, also 
in this part of the thesis, there is a description of a novel aspects of a well 
known phenotype associated with immune dysfunction.  In particular, in this 
case we characterized an unappreciated relationship between an impairment 
of Th1 induction due to alteration of IL-12R signalling and high levels of 
serum IgE but in the absence of HIES.  Moreover, since abnormalities of IL-
12 signaling pathway is not sufficient per se to cause an allergic disease in 
children, in that the prevalence of asthma, eczema and rhinoconjunctivitis is 
similar in patients with or without genetic alteration of IFN-  or IL-12R 1 
[112], these data could imply a link between infections and allergy in 
children, even though this matter is still under debate and no conclusive 
demonstration is available [113].  In the light of this consideration, a better 
understanding of the molecular mechanisms governing Th1/Th2 homeostasis 
may help to ameliorate the overall management of these patients.  
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Technologies 
 
Nude/SCID and DGS patients 
The patients included in the first part of the study were children affected 
by rare primary immunodeficiencies including Nude/SCID and DGS mostly 
identified at the Unit of Immunology of the Department of Pediatrics at the 
“Federico II” University of Naples where they were followed.  Moreover, 
other patients were identified through clinical and molecular diagnostic 
criteria according to the European Society of Immunodeficiencies.  DGS 
patients were selected for the presence of one of the following presenting 
signs: 
- deletion of the Cr. 22q11.2, studied by FISH analysis 
- thymic aplasia, agenesis and hypoplasia 
and for the concomitant presence of the following typical 
DGS features, such as: 
- congenital cardiopathy 
- hypoparathyroidism/hypocalcemy 
- dysmorphism 
- microcephaly 
Moreover, Nude/SCID patients were selected for the presence of: 
- FOXN1 gene mutation 
- thymic agenesis 
- alopecia 
- nail dystrophy 
 
DNA analysis 
After a written informed consent was obtained from parents, genomic 
DNA was extracted by standard procedures from villous and whole blood 
and processed.  FOXN1 DNA analysis was performed according to a 
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polymerase chain reaction (PCR) assay previously described.[48]  Briefly, a 
PCR fragment containing exon 4 of the FOXN1 gene (formerly named exon 
5) was amplified using the primers exon 5F: 5#-
CTTCTGGAGCGCAGGTTGTC-3# and exon 5R: 5#-
TAAATGAAGCTCCCTCTGGC-3#.  The PCR product was sequenced 
using an ABI prism 310 Genetic Analyzer (Applied Byosystems Inc.). 
 
Microsatellite analysis for maternal contamination CBMC 
To test maternal contamination, multiplex-PCR of 15 highly polymorphic 
autosomal short tandem repeat loci (D8S1179, D21S11, D7S820, CSF1PO, 
D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWA, TPOX, 
D18S51, D5S818, FGA) was performed on DNA samples from cord blood 
using AmpFlSTR® Identifiler™ PCR Amplification Kit (Applied 
Biosystems). 
 
Cell staining and proliferation assay of Nude/SCID and DGS 
lymphocytes 
After written consent, cord blood mononuclear cells (CBMCs) and 
peripheral blood mononuclear cells (PBMCs) were isolated from Nude/SCID 
fetus and control human fetus, matched for the same gestational ageand from 
other Nude/SCID patients and DGS patients, respectively, by density 
gradient centrifugation over Ficoll-Hypaque (Biochrom).  Cell suspensions 
were prepared in RPMI 1640 medium.  CBMC and PBMC were cultured in 
triplicate in 96-well U-bottomed microtiter plates and after stimulation with 8 
g/mL phytohemagglutinin (PHA), with 10 µg/mL PWM, 8.25 µg/mL Con-
A and 1 ng/mL and 0.1 ng/mL anti-CD3 mAb, previously precoated on tissue 
culture plates for cross-linking, cell proliferation was determined by 
incorporation of tritiated thymidine for 72 hours of culture.  In the 
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experiment performed in Hyper IgE study also the Phorbol-12-myristate-13-
acetate (PMA; 20 ng/ml) and ionomycin (0.5 mM) were evaluated. 
CBMC were stained with the appropriate antibodies: CD45, CD34, 
CD19, CD4, CD8, CD62L (Immunotech Coulter) CD3, CD16, CD56, CD7, 
CD45RA, (BD Pharmingen) on ice, washed and analyzed using a 
FACSCanto II flowcytometer Becton Dickinson.  Data were analyzed using 
FACSDiva software.  
 
MRI imaging of the fetal brain 
Brain MRI study was performed at 3 Tesla (Magnetom TRIO, Siemens, 
Germany) using a 3D low-angle, gradient-echo sequence (TR/TE 572/3.7 
msec, FA 9°, FOV150mm, acquisition matrix 144x256, slice thickness 
600mm, using a quadrature volumetric coil) providing a T1w volume which 
was resliced along axial, coronal and sagittal planes.  Images were processed 
using GIMP (http://www.gimp.org) to remove paraformaldehyde 
background.   
 
Subjects included in Hyper IgE study 
Twenty patients with elevated IgE levels and history of allergy were 
enrolled into the study.  Sixteen patients were affected by asthma, 3 of them 
also by rhinitis, and 4 had a history of atopic dermatitis.  The patients divided 
in two subgroups on the basis of IgE levels: group A consisted of 10 patients, 
10 males, range of age 5-15 yr, with very high serum IgE levels (> 2000 
kU/l, range 2152-5000 kU/l); group B consisted of 10 patients, 9 males, 
range of age 6-15 yr, with high serum IgE levels (IgE value between the age 
specific mean ± 2SD and 2000 kU/l, range 93-1152 kU/l).  Twenty healthy 
controls, 16 males range of age 6-15 yr (IgE range 85-100 kU/l), were also 
studied.  Informed consent was obtained when required.  No difference was 
found between group A and B in either the number per year or the severity of 
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allergic manifestations.  The Hyper-IgE syndrome (HIES) was excluded by 
the absence of typical clinical and immunological features [110].  In 
particular, no eczema and recurrent skin infections, facial, skeletal and 
dentition anomalies were observed.  Other conditions accompained by 
elevated serum IgE concentration, including AIDS, helminths and parasitic 
infections were also excluded by clinical and laboratoristic features.  The 
study has been approved by the applicable Institutional Review Board. 
 
Generation of Th1 cell lines  
Th1 cell lines were generated by stimulating PBMC with PHA (8 g/ml) 
or, in a few experiments, with  PHA + IFN-  (1000 U/ml, ICN, Biomedical, 
OH) for 72 hours in complete tissue culture medium.  These cells usually 
widely express high affinity IL-12R. 
 
Analysis of STAT4 activation   
PHA-induced blasts were made quiescent by 12 hours incubation in 
RPMI supplemented with 2.5% FCS at RT, and further stimulated with rIL-
12 (Genetics Institute, Cambridge, MA) at a concentration of 10-100 U/ml 
for 10 minutes.  After the appropriate stimuli, 3-5 x 10
6
 cells were lysed in 
buffer containing 20 mM Tris, pH 8, 10% glycerol, 137 mM NaCl, 1% 
Nonidet P-40, 10 mmol EDTA, 1 mM phenyl methane sulfonyl fluoride 
(PMSF), 1 mM sodium orthovanadatum (Na3Vo4), 5 g/ml leupeptin and 5 
g/ml aprotinin.  Proteins were resolved by 10% SDS- polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes 
and then blocked with 5% bovine serum albumin.  Immunoblotting was 
performed by a 2-4 hours incubation with anti-STAT4 monoclonal antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA).  Signals were detected using 
chemiluminescence (ECL system, Amersham, Buckinghamshire, England).  
The low migration supershifted form of STAT4 indicates the presence of the 
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protein in its activated/phosphorylated form [114].  Densitometric analysis 
was performed to evaluate the overall amount of the protein and the amount 
of its supershifted form.  
 
Membrane expression of 1 and 2 chains of IL-12R on T cells 
After washing in PBS, cells were incubated for 20 minutes sequentially 
with murine anti- 1 or anti- 2 chain (25 l) of IL-12R (kindly provided by 
Dr. Jerome Ritz, Dana Farber Cancer Institute, Boston, MA), IgG1 isotype 
control Ab, 10 l FITC-conjugated goat anti-mouse IgG Ab (Becton 
Dickinson, San Jose, CA), and 5 l anti-CD4 PE Ab (Becton Dickinson, San 
Jose, CA).  After staining, the expression of IL-12R- 1 and 2 on CD4
+
 cells 
was determined with flow cytometer (Becton Dickinson) by gating on the 
CD4
+
 population.   
 
Analysis of IL-12R- 2 chain RNA expression  
Total cellular RNA was prepared using Trizol reagent method (Sigma 
Chemical Co., St. Louis, MO); 1 g of total RNA was reverse transcribed 
into cDNA using ExpandTM Reverse transcriptase according to the 
manufacturer's protocol (Boehringer Manneheim, Germany).  The cDNA was 
PCR amplified (94°C, 1 minute; 55°C, 1 minute; 72°C,1 minute for 30 
cycles) using specific primers for IL-12R- 2: sense primer 
GGAGAGATGAGGGACTGGT and antisense primer 
TCACCAGCAGCTGTCAGAG.  Each PCR mixture consisted of 3 l of 
cDNA, 1 l of each primer (concentration from Kathy), 0.2 mM dNTP and 
2.5 U of Taq DNA polymerase (Life Technologies LTD, Paisley, Scotland).  
These reactions were carried out in a buffer containing 25 mM MgCl2, 200 
mM Tris-HCl and 500 mM KCl.  To monitor the amount of RNA, -actin 
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mRNA expression was used.  PCR products were separated in a 1% agarose 
gel and viewed after ethidium bromide staining.  
 
A-T Patients  
Blood samples were obtained from six consecutive patients (3 males), of 
5, 6, 14, 15, 27 and 29 years of age, respectively (mean age 16.3 years, range 
5-29 years), affected with A-T.  The patients, upon written consent, received 
a cycle of oral betamethasone at the dosage of 0.1 mg/kg/day for 10 days 
divided every 12 hours.  No antioxidants, as N-acetyl cysteine, vitamin E or 
alphalipoic acid, were given to the patients during the two years preceding 
the trial.  The clinical evaluations were carried out before therapy (T0), 48 h 
from the beginning (T48), at the end of the therapy (T10d) and, eventually, 7 
days from the withdrawal (T7 off therapy).  The neurological evaluation was 
performed through the Scale for the Assessment and Rating of Ataxia 
(SARA).   
 
Determination of lipid peroxidation 
Cells (0.8x10
5
) were lysed by freeze and thaw in 10 mM TRIS pH 7.5 
and the lipid peroxides were assessed with Cayman Chemical Company 
assay kit (Ann Arbor, Michigan, USA), according to the manufacturer’s 
instruction. This kit measures malonaldehyde (MDA) and 4-hydroxyalkenals 
that result from peroxidation of polyunsaturated fatty acids.  The samples 
were normalized for cell number. 
 
Evaluation of intracellular glutathione  
The cells were lysed by freeze and thaw.  Cellular levels of GSH were 
determined using DIGT-250 GSH colorimetric assay kit (BioAssay Systems, 
California, USA).  Cells (0.8x10
5
) were treated for 48 h with various agents 
and collected by centrifugation at 1300 g for 10 min at 4°C.  All the samples 
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were analyzed following manufacturer’s instructions.  Optical density (OD)-
values were read at 412 nm.  The samples were normalized for cell number. 
 
Measurement of intracellular ROS 
The cellular ROS accumulation was measured using the 2′, 7′-
dichlorofluorescein diacetate (DCFH-DA) method.  DCFH-DA is a non-
fluorescent compound, and it can be enzymatically converted to highly 
fluorescent compound, DCF, in the presence of ROS. After and before 
exposure to betamethasone, 1x10
6
 cells were treated with 5 μM DCFH-DA at 
37°C for 20 min, at 5% CO2, washed with PBS, collected and analyzed 
immediately on a FACScan flow cytometer (Becton Dickinson, New Jersey, 
USA) equipped with an argon laser emitting at 488 nm.  Cell Quest software 
(Becton Dickinson, New Jersey, USA) was used to acquire and evaluate all 
the events. 
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Summary 
 
In the last thirty years of the 20th century, a formidable numbers of 
scientific discoveries in the field of PIDs were made.  Many scientific papers 
have been published on the molecular and cellular basis of the immune 
response and on the mechanisms involved in the correct ontogeny of immune 
system components.  Today we know the genetic and molecular basis of the 
principal mechanisms involved in the immune response, thus it’s possible to 
classify immune diseases in different way, by different points of view.  In 
this thesis, during the three years of my PhD program, I tried to group the 
congenital immunodeficiencies on the basis of the altered immune function 
and on the basis of the cell type where the mutated genes are expressed in 
order to perform a novel characterization of such diseases through the 
combination of clinical, cellular, functional and molecular approaches.    
In particular, my research work was focused on the study at both 
molecular and clinical levels of the Nude/SCID phenotype as the real human 
model of athymia in comparison with the DiGeorge syndrome which was 
erroneously considered for long time the human counterpart of the Nude 
murine model.   
Moreover, in this context, I also participated to better define the 
functional role of FOXN1 transcription factor in the development of the 
pleiotropic aspects of the Nude/SCID syndrome.  From this study, FOXN1 
emerged as a cofactor in the development and differentiation of some 
structures in the central nervous system.  Of note, these immunodeficiencies 
are due to mutated genes expressed in non hematopoietic cells. 
In addition, I participated to the study of patients affected with Ataxia 
Telangiectasia (A-T) whose causing gene is not selectively expressed in the 
hematopoietic compartment and related to cerebellar functions.  In this 
context I contributed to evaluate whether the beneficial effect of 
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betamethasone therapy in (A-T) patients could be mediated by interference in 
ROS generation/neutralization process.  Our research led to conclude that 
betamethasone response in A-T patients is inversely correlated to cerebellar 
atrophy and directly to antioxidative capacity. 
During my PhD course I also participate to the study of some 
immunodeficiencies due to alterations of genes expressed in hematopoietic 
cells giving a contribution to the description of the mechanism altered in the 
case of high serum level of IgE.  The data obtained in this context revealed 
the alteration of IL-12R signaling in a group of patients with high levels of 
serum IgE but without Hyper IgE Syndrome. 
Overall, all my studies were designed in order to better understand the 
mechanisms involved in the pathogenesis of such immune diseases.  The 
results of this thesis by adding novel information in this field could be useful 
both in the clinical practice and in the basic research of immune disorders by 
revealing unknown aspects of these diseases. 
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of the disease”. 
 Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale – Call for 
MIUR Application 2009, with a project entitled: “Studio dell'ontogenesi delle 
: allestimento di "scaffold" 
tridimensionali per la generazione in vitro di cellule T e Treg da precursori 
ematopoietici.” 
 Fondazione Cariplo – Call for application in Ricerca Scientifica in ambito 
biomedico 2010, with a project entitled: “Functional cellular and molecular studies 
to elucidate the immune pathogenesis of multiple autoimmune manifestations of 
childhood”.  
 “TELETHON GRANT PROPOSALS-Call for Applications 2010” with a 
project entitled: “Characterization of the T−cell ontogeny defect in the human 
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